Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936475 | 0.94 | GFER (0.60) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL13401130 | 0.93 | ALDH1A1 (0.50) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL1936395 | 0.86 | LMNA (0.50) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL13435514 | 0.84 | KMT2A (0.48) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL13435293 | 0.84 | KMT2A (0.48) | GFERALDH1A1GAALMNAMAPT | |
| SCHEMBL1936323 | 0.84 | KDM4E (0.59) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL1935240 | 0.83 | ALDH1A1 (0.51) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL3228650 | 0.82 | ALDH1A1 (0.51) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL3234741 | 0.82 | ALDH1A1 (0.48) | GFERALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL3234738 | 0.82 | ALDH1A1 (0.48) | GFERALDH1A1GAALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2331539-A2 | 1,3,4,6,7,11B-HEXAHYDRO-BENZO[ALPHA]QUINOLIZINES FOR THE TREATMENT OF HYPERKINETIC MOVEMENT AND RELATED DISORDERS | Biovail Laboratories International (Barbados) SRL (BB) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010026436-A2 | PHARMACEUTICAL COMPOUNDS | BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL (BB) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | GFER 2485/4885ALDH1A1 926/4885GAA 822/4885 |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | UGT2B7, CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GFER 3891/4885ALDH1A1 292/4885GAA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.